VARGATEF®: extending survival, even where you may not expect it

See Indication

VARGATEF®: extending survival, even where you may not expect it

See Indication

Clinical library and resources

LUME-Lung 1 trial: efficacy, VARGATEF® + Docetaxel vs Placebo + Docetaxel
Watch the mechanism of action video
Countries where VARGATEF® is approved
Countries
Indications & Usage

VARGATEF® is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. 1

References
  1. VARGATEF® SmPC
FooterMobile Back to Top